P049 LIGELIZUMAB ACHIEVES FREEDOM FROM DISEASE ACTIVITY IN CHRONIC SPONTANEOUS URTICARIA REGARDLESS OF PREVIOUS H1-ANTIHISTAMINE DOSE

Anti-IgE therapy is recommended for patients with uncontrolled chronic spontaneous urticaria (CSU) despite treatment with H1-antihistamines. Here, we analyze the effect of ligelizumab, a next-generation anti-IgE antibody, in CSU patients who were treated with locally approved or escalated doses of H1-antihistamines.